Variations in the Management of Low-Grade Serous Carcinoma of the Ovary: A Global Survey
Open Access
- 31 December 2024
- journal article
- research article
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 23 (1) , 1-10
Abstract
Objective: Low-grade serous carcinoma (LGSOC) constituting < 15% of ovarian or peritoneal serous carcinomas differs distinctly from high-grade serous ovarian carcinoma (HGSOC). This global survey investigates the variations in managing LGSOC, acknowledging its unique characteristics and the absence of a consensus on optimal management. Methods: A voluntary non-incentivized global survey gathered responses from 203 practitioners across 50 countries and 7 continents. Approved by the Institutional Ethics Committee, it encompassed 21 questions focusing on demographics, diagnosis, and management practices. Descriptive statistics and Fisher’s exact test analyzed the data. Results: Demographically diverse responses were obtained with the majority from India (39.9%) and Colombia (5.4%). Gynecologic oncologists predominated (73.10%), with varied practice settings. Most practitioners considered LGSOC distinct (95.57%). Diagnosis criteria showed institutional variations. In managing apparent inoperable stage III C LGSOC approaches varied: neoadjuvant chemotherapy (54.78%), upfront surgery (35.69%), and neoadjuvant hormone therapy (8.54%). Adjuvant management demonstrated heterogeneity. Notably, there was no significant association between the continent and the offered adjuvant treatment for optimally cytoreduced stage III C LGSOC (p = 0.556; Fisher’s exact test). For recurrent disease, hormonal therapy (30.54%) and chemotherapy (27.59%) were common choices. MEK inhibitors were infrequently used. Fertility preservation was favored (71%), and HIPEC was not widely considered (81.28%). Genetic testing opinions varied: routine testing (28.7%), no recommendation (45.32%), and testing in recurrent settings (16.75%). Conclusion: This survey exposes global disparities in LGSOC management, highlighting the need for standardized guidelines to address challenges in diagnosis and management. International collaboration is advocated to enhance uniformity in healthcare practices for LGSOC.Keywords
Funding Information
- Tata Memorial Hospital - TMC
This publication has 23 references indexed in Scilit:
- A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinomaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2021
- Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United StatesGynecologic Oncology, 2020
- The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistanceGynecologic Oncology, 2020
- PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsGynecologic Oncology, 2019
- Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future DirectionsCurrent Treatment Options in Oncology, 2018
- Low-grade serous ovarian cancer: A reviewGynecologic Oncology, 2016
- The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancerGynecologic Oncology, 2015
- Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcomeCancer Cytopathology, 2012
- Reclassification of serous ovarian carcinoma by a 2‐tier systemCancer, 2011
- Recurrent low-grade serous ovarian carcinoma is relatively chemoresistantGynecologic Oncology, 2009